Teladoc Health stock has had a tough run over the past five years, yet current valuation checks now point to the shares trading at a discount, with the Discounted Cash Flow (DCF) intrinsic value estimate and market multiples both suggesting the market price may sit below what the company’s fundamentals imply.

• Over the past five years Teladoc Health has declined 94.0%, which puts the current valuation in the context of a long period of weak shareholder returns.
• Investors are watching how the Walmart partnership and broader insurance coverage can support revenue and cash flow over time, while competition from large tech and healthcare players remains a key risk to sustaining that value.
• Teladoc Health screens as undervalued in 5 of 6 valuation checks, and the Discounted Cash Flow (DCF) estimate points to the shares trading about 38.8% below intrinsic value, which together suggest the broader framework leans cheap.

The issue now is whether Teladoc Health’s business can deliver the cash flows needed to close the gap between the current share price and this intrinsic value estimate.

Is Teladoc Health Still Cheap on Cash Flow?

The Discounted Cash Flow (DCF) model uses Teladoc Health’s projected free cash flows to estimate what the stock could be worth today. Teladoc Health generated about $148.1 million of free cash flow over the last twelve months, and the DCF framework assumes these cash flows continue growing rather than shrinking over the coming years.

On that basis, the model arrives at an intrinsic value of about $15 per share. This figure is roughly 38.8% above the current share price implied by the inputs. The recent Walmart partnership and insurance expansion focus on building utilization and cash generation, and the current discount indicates that the market remains cautious even as cash flows are modeled to improve within this framework.

Overall, the Discounted Cash Flow (DCF) workup suggests Teladoc Health stock appears undervalued relative to the cash flows implied in this model, based on these assumptions.

Our Discounted Cash Flow (DCF) analysis suggests Teladoc Health is undervalued by 38.8%. Track this in your watchlist or portfolio, or discover 44 more high quality undervalued stocks.

Is Teladoc Health Still Cheap on Sales?

P/S is a useful cross check for Teladoc Health because the company is still reporting accounting losses, so earnings based ratios like P/E are less informative. On sales, Teladoc Health currently trades at a P/S of about 0.7x, compared with a Healthcare Services industry average of roughly 2.5x and a broader peer group average of about 5.0x.

The tailored fair P/S ratio for Teladoc Health, which considers its size, margins, sector and risk profile, is about 2.0x. That is roughly three times the current P/S and suggests the stock screens as undervalued on this framework, even after accounting for company specific risks and competition in virtual care.

Overall, Teladoc Health appears undervalued on the P/S multiple, with the current share price indicating a significant discount relative to the level implied by its revenue base and fair ratio benchmark.

The Teladoc Health Narrative: What Would Justify Today's Price?

For Teladoc Health, Simply Wall St Narratives pick up where the valuation work leaves off by spelling out which combinations of future growth, margins and earnings would need to occur for the stock to be worth materially more or less than today’s price. Each Narrative ties Teladoc Health's fair value to a particular mix of potential catalysts and risks so you can track over time which interpretation of the company’s story appears closer to reality on the Community page.

Teladoc Health splits opinion, with one camp seeing a discounted turnaround story and the other viewing the stock as already pricing in a lot of the recovery.

Bull case: 12% undervalued

"Teladoc's investments in advanced AI-driven care orchestration, leveraging its proprietary tech stack and millions of annual engagement points, are poised to shift its platform from transactional virtual care to continuous, proactive health management..."

Bear case: 25% overvalued

"The transition from higher-margin cash pay users to lower-margin insurance-based revenue in the BetterHelp segment is expected to depress overall gross margins, and management acknowledges insurance margins are a lot lower with no clear visibility on future equilibrium..."

Do you think there's more to the story for Teladoc Health? Head over to our Community to see what others are saying!

The Bottom Line

Teladoc Health screens as undervalued on both the Discounted Cash Flow (DCF) intrinsic value estimate and revenue based multiples, so the key question is whether the business can sustain the cash flows and margins those models assume. The broader valuation checks are supportive, which means the current discount looks more like a judgment on execution and competitive risk than a simple mispricing. From here, the crux is whether Teladoc Health can convert its partnerships and scale into durable, profitable growth rather than a value trap, where the apparent upside remains theoretical.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.